UBC Type 1 diabetes drug trial seeks to end injections

Researchers at UBC are looking for young people recently diagnosed with Type 1 diabetes for a pilot study to see if an existing drug can curb the need for insulin injections.

Study aims to see if drug ustekinumab could curb or eliminate need for insulin injections

Judith Garcia, 19, fills a syringe as she prepares to give herself an injection of insulin to manage her diabetes. A new UBC study aims to test an alternative to the injections for those with Type 1 diabetes. (Reed Saxon/Associated Press)

Researchers at UBC are looking for young people recently diagnosed with Type 1 diabetes for a pilot study to see if an existing drug can curb the need for insulin injections.

UBC Associate Professor Dr. Tom Elliott is working with B.C. Diabetes on the study.

They want to see if a drug typically used for psoriasis conditions can reduce or even eliminate insulin dependence.

"It's a chance to get a cure for this, which is unheard of so far," said Elliott.

"My research team has identified a molecule that's been used very successfully for treating a form of arthritis, that looks like a very good candidate to stop the destruction of insulin-secreting cells that is the cause of Type 1 diabetes."

The drug ustekinumab, which is sold commercially as Stelara, is not approved for treating Type 1 diabetes, but it's going to be made available free of charge to 20 people in the pilot study in Vancouver.

One participant is Sierra Dean, 19, who was diagnosed with Type 1 diabetes two months ago. She didn't know much about the disease until she found out she has it, she said.

"Having to learn to give myself injections as well as carb count, and the exercise needed. It's been a huge learning curve," said Dean.

The researchers are still looking for participants between the ages of 18 and 35 who were diagnosed with Type 1 diabetes within the last 100 days. More eligibility information can be found on the B.C. Diabetes website.
 

Comments

To encourage thoughtful and respectful conversations, first and last names will appear with each submission to CBC/Radio-Canada's online communities (except in children and youth-oriented communities). Pseudonyms will no longer be permitted.

By submitting a comment, you accept that CBC has the right to reproduce and publish that comment in whole or in part, in any manner CBC chooses. Please note that CBC does not endorse the opinions expressed in comments. Comments on this story are moderated according to our Submission Guidelines. Comments are welcome while open. We reserve the right to close comments at any time.